Click ingredient brand name for product website.
| Code | Product Name | Standardization | Functional Activity† |
|---|---|---|---|
| 0301 | Calebin A (1) New CurCousin™ GRAS AFFIRMED |
99% Calebin A | Joint support Liver health support Metabolic health support Weight management support |
| 0336 | Chrysin | 97% Dihydroxyflavone | Anti-inflammatory support Cognitive health support Sports nutrition |
| 0522 | Diindolylmethane (DIM) | 98% DIM | Antioxidant support Bone health |
| 0472 | Forskolin Carbonate | 98% Forskolin Carbonate | Weight management support |
| 0912 | Indole-3-Carbinol | 99.6% Indole-3-Carbinol | Antioxidant support Joint support |
| 2100 | Ipriflavone | 98.5% Ipriflavone | Bone health |
| 1458 |
Oxyresveratrol
(2) OxyResvenox® |
95% Oxyresveratrol | Antioxidant support Immune support Support heart health |
| 1819 | Resveratrol (2) Resvenox® |
99% Resveratrol | Antioxidant support Immune support Support heart health |
| 2022 | Tetrahydrocurcuminoids ODS Curcumin C3 Reduct® ODS |
95% Tetrahydrocurcuminoids | Anti-inflammatory support Antioxidant support Oral health |
SPATENT
(1) Calebin A (CurCousin™ )
US 8,933,121; US 9,328,330; AU2012366253; AU2014203122; CA2857543; JP6374716; KR10-1702702; NZ614076; NZ 715053; RU2543334; SG192695; ZA2013/05918; ZL201280012577.3: Anti-obesity potential of calebin A. US 9,610,273; US 9,668,999; AU2014202312; CA2850999; CA2963383; EA027148; EP2937084; HK1210590; I-622384; JP6263707; KR10-1647549; NZ624269; MY-170067-A; PH1-2014-000244: Method for the treatment of hypercholesterolemia
IDP000064827: Calebin A and its effect on hypercholesterolemia
US 9,220,703; AU2014201769; CA2935898;EP2893926; JP6142446; KR10-1685263; KR10-1685333; MY-175867-A; NZ622909; PH1-2016-501138; SG11201605336Y: Composition and method for the protection of articular cartilage
EA027614: Use of calebin A to protect mammalian articular cartilage from pathological damage
US 9,365,486; AU2014203764; CA2858126; EA027726; EP2963007; HK1217689; JP6490927; KR10-1629561; NZ627247: Synthesis of calebin A and its biologically active analogs
HK1210028: Calebin A for articular cartilage
EP3085370: Calebin A for inducing lipolysis
US 9,737,502; CA2893321; IDP000067993; JP6336943; KR10-1763474; MY-182000-A; PH1-2015-000188; RU2643297; SG10201503805X: Calebin A for hepatic steatosis
US 9,539,232; CA2941050; RU2653103: Calebin A for osteoporosis
EP2663185; HK1190874: Calebin A for use in the treatment of inflammation and obesity
EP3085370: Calebin A for inducing lipolysis
(2) Oxyresvenox® / Resvenox®
US 7,253,324: Process for the synthesis of biologically active oxygenated compounds by dealkylation of the corresponding alkylethers
†Disclaimer
These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
